Crossmark

Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804)

Crossref DOI link: https://doi.org/10.1007/s12032-022-01755-3

Published Online: 2022-08-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakamura, Atsushi

Harada, Masao

Watanabe, Kana

Harada, Toshiyuki

Inoue, Akira

Sugawara, Shunichi https://orcid.org/0000-0002-3427-4558
License Information

Text and Data Mining valid from 2022-08-16

Version of Record valid from 2022-08-16
More Information

Article History

Received: 28 March 2022

Accepted: 17 May 2022

First Online: 16 August 2022

Declarations

:

: Atsushi Nakamura received honoraria from MSD and Eli Lilly and Company. Akira Inoue received honoraria from Taiho Pharmaceutical. Shunichi Sugawara received honoraria from Taiho Pharmaceutical. The other authors declare no conflicts of interest.

: Our manuscript is sufficiently anonymized.

Document is current

Any future updates will be listed below